Patents by Inventor Bandana Chatterjee

Bandana Chatterjee has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATION THERAPY FOR CASTRATION-RESISTANT PROSTRATE CANCER
    Publication number: 20190038641
    Abstract: Certain embodiments of the current disclosure are directed to a combined vitamin D (calcitriol or analog thereof) and androgen therapy that reduces the growth of mCRPC in humans. In certain aspects a new combined vitamin D and androgen medication formulation is described that controls advanced prostate cancer. Calcitriol, calcitriol analogs, and androgens are referred to herein as therapeutic agents or agents.
    Type: Application
    Filed: February 3, 2017
    Publication date: February 7, 2019
    Applicant: The Board of Regents of the University of Texas System
    Inventors: Bandana CHATTERJEE, Sulgi PARK, Chung S. SONG
  • Methods and compositions for treatment of cancer using oncolytic RSV activity
    Patent number: 9241998
    Abstract: The present invention relates generally to methods and compositions employing the oncolytic activity of respiratory syncytial virus (RSV) to treat cancer and other neoplastic disorders.
    Type: Grant
    Filed: May 21, 2008
    Date of Patent: January 26, 2016
    Assignee: Board of Regents, The University of Texas System
    Inventors: Santanu Bose, Bandana Chatterjee
  • METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER USING ONCOLYTIC RSV ACTIVITY
    Publication number: 20100303839
    Abstract: The present invention relates generally to methods and compositions employing the oncolytic activity of respiratory syncytial virus (RSV) to treat cancer and other neoplastic disorders.
    Type: Application
    Filed: May 21, 2008
    Publication date: December 2, 2010
    Inventors: Santanu Bose, Bandana Chatterjee
  • Estrogen receptor site-specific ribozymes and uses thereof for estrogen dependent tumors
    Patent number: 7179593
    Abstract: Highly specific hammerhead ribozymes are provided that human target estrogen receptor mRNA. These ribozymes, designated RZ1 through RZ7 provide predictable mRNA cleavage products. Methods for inhibiting estrogen-dependent tumor growth, such as that characteristic of breast cancer, are also provided employing these ribozymes. One or both of the ribozymes may be used together or separately with equal efficiency. The ribozymes possess a sequence region with a catalytic core that provides the attributed catalytic activity to these ribozymes.
    Type: Grant
    Filed: June 2, 2000
    Date of Patent: February 20, 2007
    Assignee: Board of Regents, The University of Texas System
    Inventors: Arun K. Roy, Yan Lavrovsky, Rakesh K. Tyagi, Chung S. Song, Bandana Chatterjee, Shuo Chen
  • Methods and compositions relating to the androgen receptor gene and uses thereof
    Patent number: 5556956
    Abstract: Disclosed are methods and compositions, including antisense and antigene constructs and pharmaceutical formulations thereof, for use in regulating androgen receptor gene expression. The promoter activity of the androgen receptor gene is herein shown to include a critical upstream acting domain with a unique sequence, the unique nucleic acid sequence corresponding to positions 1697 and 2084, particularly between positions 1697 and 1717, as defined in SEQ ID NO:1. The AR gene promoter sequence, herein characterized as having a a particular nucleotide sequence defined between nucleotides 1697 and 2084 of SEQ ID NO:1, is characterized as important in the regulation of androgen receptor gene expression.
    Type: Grant
    Filed: November 4, 1993
    Date of Patent: September 17, 1996
    Assignee: Board of Regents, The University of Texas System
    Inventors: Arun K. Roy, Bandana Chatterjee